Canine 1-DAPPv+Cv
Proven combination vaccine that offers broad protection for dogs against common viral strains.
Product Description
CANINE 1-DAPPv+Cv provides protection against a combination of viruses.
Canine Distemper Virus, Canine Adenovirus Type 2, Canine Parainfluenza Virus, Canine Parvovirus (modified live viruses), Coronavirus (inactivated virus).
- Proven effective against all known strains of canine parvovirus (CPV), including CPV-2c1-3
- Contains CPV-2b, one of the most prevalent field strains of parvovirus
- High antigenic mass (titer), low passage parvovirus vaccine
- Overrides maternal antibodies in young puppies1
- Proven effective against 2 types of adenovirus that cause hepatitis and respiratory disease in dogs
- Proven effective against commonly spread canine viruses, coronavirus, distemper, adenovirus types 1 and 2, parainfluenza and parvovirus, in 1 formula
Indications:
Shown to be effective for vaccination of healthy dogs 6 weeks of age or older against canine distemper virus, canine adenovirus type 1 (hepatitis), canine adenovirus type 2 (respiratory disease), canine parainfluenza virus, canine parvovirus and canine coronavirus.
Recommended for use in healthy dogs 6 weeks of age or older.
ADMINISTRATION AND DOSAGE
- Subcutaneous or intramuscular injection
- Two 1 mL doses given 2-4 weeks apart
- Two doses are required for primary immunization
- Contact your veterinarian or manufacturer for more information on revaccination frequency
- Available in a 25 x 1 mL dose presentation
ALSO AVAILABLE IN OTHER FORMULATIONS
DISEASE INFORMATION
Professional Resources and Educational Materials
Keep your clinic and staff informed and aware of diseases and outbreaks.
View More Nobivac ResourcesReferences
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen
Global